【摘要】 目的 分析吲哚美辛栓所致不良反应的临床特征、相关因素,为临床药物治疗中药品不良反应的防治提供参考依据。方法 检索1986年—2009年中国生物医学文献系统吲哚美辛栓的不良反应资料,并加以分析研究。结果 得到符合标准的患者24例,不良反应报告中男性多于女性;不良反应以全身性损害最多(12例,50.00%),其次为皮肤及附件损害(2例,8.33%)、循环系统损害(2例,8.33%)、消化系统损害(2例,8.33%);不良反应较为严重。结论 患者的年龄、性别等因素能影响不良反应的发生,临床应特别注意吲哚美辛栓引起的休克。
摘要:目的: 系统评价非布索坦治疗痛风的疗效及安全性。 方法 :计算机检索PubMed、EMBASE、SCI、CBM、CNKI、VIP、万方数据库及Cochrane图书馆,手工补充检索;纳入非布索坦治疗痛风的随机对照试验(RCT);进行方法学质量评价和Meta分析。 结果 :共纳入3个RCT(受试者1985例),A级文献1篇,B级文献2篇。Meta分析结果显示:最后3月血清尿酸(SU)持续低于60 mg/dl患者数、随访结束时SU低于60 mg/dl患者数非布索坦组与对照组差异均有统计学意义;治疗相关不良事件发生数与安慰剂组差异无统计学意义,与别嘌呤组差异有统计学意义。 结论 :基于当前证据,非布索坦治疗痛风,能有效降低SU含量,减少治疗相关不良事件发生率。Abstract: Objective: Assessing the effectiveness and safety of febuxostat for the treatment of gout. Methods :Randomized controlled trails(RCT) of febuxostat for the treatment of gout were gathered from the Cochrane Library、PubMed、EMBASE、SCI、CBM、CNKI、VIP、Wangfang Database, other relative researches were handsearched, each RCT was methodological quality evaluated, then analyzed by software RevMan50 Results :A total of 3 RCTs were collected (involving 1985 subjects); 1 was graded A, 2 were B; according to the Metaanalysis: the differences of subjects with last 3 monthly serum urate(SU)＜60mg/dl and subjects with SU＜60mg/dl at final visits were significant; treatmentrelated adverse events between febuxostat and allopurinol was significant different, but not significant difference between febuxostat and placebo. Conclusion : According to the evidence currently, febuxostat could reduce SU and the episodes of treatmentrelated adverse events.
ObjectiveTo study the techniques of mimicking multifactors induced acute pancreatitis in rat by slow-release pump. MethodsSeventy-five healthy SD rats were randomly divided into slowrelease pump group (SRP group), traditional group (TAP group), and sham operation group (SO group). Four percent sodium taurocholate was injected through pancreatobiliary duct of rats directly and retrogradely in TAP group and by slow-release pump in SRP, which mimicked AP pathogenesis from selfdigestion, obstruction, cytokine activation, and many other mechanisms. Detection of serum amylase and pancreatic myeloperoxidase (MPO) leves, observation of pancreatic histological changes and scoring of pancreatitis severity in three groups were performed at 1, 6, 12, and 24 h after successful model induction, respectively. ResultsSerum amylase and pancreatic MPO levels, and the pathological grading score of rats were significantly higher in SRP and TAP groups than in SO group at different time point (Plt;0.05 or Plt;0.01), while they were lower in SRP group than in TAP group with a slowly rising tendency, and there were significant differences at 6 and 12 h time point, respectively (Plt;0.05 or Plt;0.01). Conclusions Slow-release pump technique can induce AP through increasing the pressure of pancreatic duct, tissue edema and sustained releasing inflammation factors by mimicking the pathophysiological process of pancreatitis. Slow-release pump can be kept in place to monitor and control the pressure of pancreatic duct. Slow-release pump method is relatively moderate and easy to manage with a lower mortality.